CPT 0518U SyncView Pain — Reimbursement & Policy | OpenPayer

Summary & Overview

CPT 0518U: SyncView Pain Plasma LC–MS/MS Drug Panel

Headline: New PLA CPT code 0518U identifies a proprietary plasma drug panel for pain and mental health medication monitoring

Lead: CPT code 0518U designates SyncView® Pain, a proprietary LC–MS/MS plasma assay from Phenomics Health™ Inc. that quantifies 90+ drugs relevant to pain management and mental health. The code enables reporting of this single-manufacturer laboratory test on claims and is relevant to payers and providers managing complex medication regimens.

What the code represents and why it matters: As a PLA CPT code, 0518U is tied to a unique commercial test and facilitates precise claims reporting for advanced toxicology and therapeutic drug monitoring. Nationally, accurate coding for high-complexity laboratory diagnostics supports administrative tracking, utilization oversight, and clinical case management for patients on multiple analgesic and psychotropic agents.

Key payers covered in the analysis: Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare are the primary payers referenced for coverage and claims processing context.

Overview of what readers will learn: This publication explains the clinical scope of the test, its service setting and billing implications, and what to expect in payers’ administrative handling of a PLA-coded LC–MS/MS panel. Readers will find benchmarks and contextual guidance on coding and claims reporting practices, policy considerations for proprietary laboratory tests, and the clinical relevance of broad-spectrum drug quantitation for pain and mental health management.

AetnaBlue Cross Blue ShieldCigna HealthUnitedHealthcareMedicare0518UCPTProprietary Laboratory AnalysisLC-MS/MSPain managementDrug monitoringClinical laboratoryTherapeutic drug monitoring

Billing Code Overview

CPT code 0518U is a Proprietary Laboratory Analyses (PLA) code that applies exclusively to the SyncView® Pain test from Phenomics Health™ Inc. The test uses liquid chromatography–tandem mass spectrometry (LC–MS/MS) to analyze plasma and measure the levels of 90 or more drugs related to pain management and mental health. The assay reports information on minimally effective doses for both prescribed and nonprescribed medications.

Service Type: Laboratory diagnostic test — Proprietary plasma drug panel using LC–MS/MS

Typical Site of Service: Clinical laboratory or outpatient phlebotomy collection site

Clinical & Coding Specifications

Clinical Context

A 48-year-old patient with chronic low back pain and coexisting anxiety is managed by a multidisciplinary pain clinic. The treating clinician has prescribed multiple medications including an opioid, a benzodiazepine, and a serotonergic antidepressant. Due to persistent pain, unclear response to therapy, concerns for drug interactions, and questions about nonprescribed substance use, the clinician orders the proprietary plasma-based LC–MS/MS panel SyncView® Pain (0518U) from Phenomics Health™ Inc. The patient presents to an outpatient phlebotomy laboratory and has a blood draw collected in accordance with the test kit instructions. The specimen is sent to the manufacturer's accredited laboratory for analysis. Results report quantitative levels for 90+ drugs relevant to pain and mental health and provide interpretation regarding minimally effective doses and potential interactions, which the ordering clinician reviews during a follow-up visit to inform medication optimization and safety monitoring.

Coding Specifications

Modifier	Description	When to Use
`00`	No modifier; standard reporting	Use when no special modifier applies and full service is billed.
`26`

CPT 0521U: Seronegative Rheumatoid Arthritis Panel

CPT-0069U-MIR-31NOW-MIR-31-3P-EXPRESSION-COLON-CANCER

CPT 0069U: miR–31–3p Expression Test for Colon Cancer

CPT-0157U-APC-MRNA-SEQUENCE-ANALYSIS-CUSTOMNEXT-RNA

CPT 0157U: APC mRNA Sequence Analysis (CustomNext® + RNA)

CPT-0360U-NODIFY-CDT-PLASMA-AUTOANTIBODY-RISK-SCORE

CPT 0360U: Nodify CDT® Plasma Autoantibody Risk Score

CPT-0116U-SNAPSHOT-ORAL-FLUID-COMPLIANCE-TEST

CPT 0116U: Snapshot Oral Fluid Compliance Test

CPT-0404U-DIVITUM-TKA-THYMIDINE-KINASE-ACTIVITY-SERUM-ASSAY

CPT 0404U: DiviTum®TKa Serum Thymidine Kinase Activity Assay

CPT-0504U-URINARY-TRACT-INFECTION-MULTIPLEX-PCR

CPT 0504U: Urinary Tract Infection Multiplex PCR Test

CPT-0429U-OMNIPATHOLOGY-OROPHARYNGEAL-HPV-PCR-TEST

CPT 0429U: Omnipathology Oropharyngeal HPV PCR Test

CPT-0575U-HEPATOTRACK-LIVER-ALLOGRAFT-REJECTION-MIRNA-RTPCR

CPT 0575U: HepatoTrack™ microRNA Test for Liver Allograft Rejection Risk

CPT-0106U-CAIRN-13C-SPIRULINA-GASTRIC-EMPTYING-BREATH-TEST

CPT 0106U: Cairn 13C–Spirulina Gastric Emptying Breath Test

Showing 1–10 of 536

Taxonomy Code	Specialty	Notes
208000000X	Anesthesiology	Pain specialists who manage complex pharmacotherapy for chronic pain often order comprehensive plasma drug panels.
208800000X	Physical Medicine & Rehabilitation	PM&R physicians coordinate multimodal pain management and may use comprehensive drug level reporting for medication optimization.
207L00000X	Psychiatry & Neurology (Psychiatry)	Psychiatrists managing psychotropic medications may use results to assess adherence and interactions in comorbid mental health conditions.
207X00000X	Internal Medicine	Primary care physicians frequently manage chronic pain and polypharmacy and may order the test for safety and dosing guidance.
363LF0000X	Clinical Laboratory	Clinical laboratory directors and pathologists oversee technical testing, reporting, and billing for proprietary laboratory analyses.

Related Diagnoses

ICD-10 Code	Description	Clinical Relevance
`G89.2`	Chronic pain, not elsewhere classified	Common indication for comprehensive drug level testing to manage analgesic therapy and evaluate polypharmacy.
`G89.4`	Chronic pain syndrome	Used when chronic pain has significant functional impact and medication optimization via measured drug levels is indicated.
`F41.1`	Generalized anxiety disorder	Coexisting mental health conditions often require psychotropic medications assessed by the panel for levels and interactions.
`F32.9`	Major depressive disorder, single episode, unspecified	Antidepressant therapy monitoring and interaction assessment are relevant for pain patients on multimodal regimens.
`M54.5`	Low back pain	A specific pain diagnosis frequently associated with long-term analgesic prescribing and monitoring needs.

Related CPT Codes

CPT Code	Description	Relationship to This Procedure
`0518U`	SyncView® Pain (Phenomics Health™ Inc.) — plasma LC–MS/MS panel measuring levels of 90+ pain- and mental health–related drugs	Proprietary laboratory analysis code for the specific test described; primary billing code for the assay and its report.
`36415`	Collection of venous blood by venipuncture	Performed at the outpatient phlebotomy site to obtain the plasma specimen sent for the `0518U` assay.
`80053`	Comprehensive metabolic panel	Common laboratory testing ordered concurrently to assess organ function (e.g., hepatic/renal) that affects drug metabolism and dosing decisions.
`80307`	Drug confirmation test, any number of drug classes; confirmation by mass spectrometry (e.g., LC–MS/MS) — qualitative or quantitative	A general drug confirmation CPT that may be used for non-proprietary mass spectrometry-based confirmations when `0518U` is not applicable.
`G0499`	Unlisted laboratory test — clinical pathology	Used in some billing workflows when a specific PLA code is not available; not typically used when `0518U` exists for this proprietary test.

OpenPayer